This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (58)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David J. Winchester, MD; Rosemary B. Duda, MD; Carey Z. August, MD; Robert A. Goldschmidt, MD; Debra M. Wruck, RN; Alfred W. Rademaker, PhD; David P. Winchester, MD; Douglas E. Merkel, MD

Arch Surg. 1990;125(7):886-889.

Abstract
• DNA flow cytometric analysis and conventional clinical factors were compared with disease outcome in 257 patients with node-negative infiltrating ductal carcinoma who had been treated between 1976 and 1983. Median follow-up was 80 months; none of the patients received adjuvant therapy. The relative prognostic importance of clinical variables, ploidy, and S-phase fraction was analyzed by Cox multivariate analysis. Ploidy was analyzable for 198 tumors and did not predict survival. Nuclear grade predicted disease-free survival for all patients. For 71 patients with diploid tumors, only high S-phase had a statistically significant association with relapse. For 127 patients with aneuploid tumors, tumor diameter predicted both disease-free survival and cancer death; histologic grade was also significant for predicting disease-free survival. In conclusion, flow cytometric determination of ploidy and S-phase fraction can provide valuable predictive information in node-negative breast cancer in addition to conventional variables.

(Arch Surg. 1990;125:886-889)

Author Affiliations
From the Departments of Surgery (Drs D. J. Winchester, D. P. Winchester, and Duda, and Ms Wruck), Pathology (Drs August and Goldschmidt), and Medical Oncology (Drs Rademaker and Merkel), Northwestern University and Evanston (Ill) Hospital.

Footnotes
Accepted for publication March 18, 1990.

Read before the 97th Annual Meeting of the Western Surgical Association, St Louis, Mo, November 14, 1989.

Reprint requests to Department of Medical Oncology, Evanston Hospital, 2650 Ridge Ave, Evanston, IL 60201 (Dr Merkel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza et al.
Ann Oncol 2005;16:1723-1739.
ABSTRACT | FULL TEXT  

Prognostic and Predictive Role of Proliferation Indices in Adjuvant Therapy of Breast Cancer
Daidone and Silvestrini
J Natl Cancer Inst Monogr 2001;2001:27-35.
ABSTRACT | FULL TEXT  

DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer
Reed et al.
Arch Surg 2000;135:1422-1426.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and High S Phase in Breast Cancer
Cobleigh et al.
JAMA 1999;281:1528-1530.
ABSTRACT | FULL TEXT  

Internal Mammary Nodal Status Is a More Reliable Prognostic Factor Than DNA Ploidy and c-erb B-2 Expression in Patients With Breast Cancer
Noguchi et al.
Arch Surg 1993;128:242-246.
ABSTRACT